Lori A. Kunkel

Dr. Kunkel has more than two decades of experience in oncology and immunology drug development and commercialization. Dr. Kunkel presently serves on the Boards of Directors of Loxo Oncology, Curis, Inc, Tocagen and Maverick Therapeutics. She was previously the acting Chief Medical Officer at Loxo and she served as Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and Proteolix, Inc (acquired by Onyx Pharmaceuticals), contributing to the approvals of cancer therapeutics IMBRUVICA® and KYPROLIS®, respectively. She has advised multiple clients including Chiron (acquired by Novartis), Genentech/Roche, Salmedics (acquired by Celgene), Stemcentrx, Inc (acquired by Abbvie), Amphivena Therapeutics, Atreca, Inc, and Verastem, Inc.

Dr. Kunkel served as a faculty member in the Division of Hematology/Oncology at the University of California, Los Angeles. Dr. Kunkel obtained a medical degree from the University of Southern California and a bachelor's degree in biology from the University of California, San Diego. She is board-certified in internal medicine and held board certifications in hematology and oncology.